Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
27 July, 2017 12:26 IST
Zydus Cadila gets USFDAs final nod for Phentermine HCl tablets
Source: IRIS | 30 Jun, 2017, 10.10AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Phentermine Hydrochloride Orally Disintegrating Tablets in strengths of 15 mg, 30 mg, and 37.5 mg.

The drug is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol or diabetes and will be produced at the group’s formulations manufacturing facility at Moraiya in Ahmedabad.

Shares of the company gained Rs 3.55, or 0.68%, to trade at Rs 525.45. The total volume of shares traded was 16,403 at the BSE (10.03 a.m., Friday).





Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
SSPDL inks JDA for development of premium residential apartments in Chennai - 27-Jul-2017 11:19
Tata Motors expands range of commercial vehicles in Philippines - 27-Jul-2017 10:22
VA Tech Wabag bags STP order worth Rs 3.86 bn - 27-Jul-2017 10:13
HCL Technologies quarterly net up 8% - 27-Jul-2017 09:09
Maruti Suzuki launches first NEXA Service workshop at Gurugram - 27-Jul-2017 08:50
Yes Bank Q1 earnings jump 31.9% to Rs 9.65 bn - 26-Jul-2017 16:11
MBL Infra selects Welspun Ent as sponsorer for two projects - 26-Jul-2017 13:43
Hero Motocorp quarterly net rises 4% - 26-Jul-2017 10:57
TD Power Systems bags order for supply of traction motor components - 26-Jul-2017 10:24
Cipla in partnership with MMV launches quality-assured RAS - 26-Jul-2017 10:19
Suzlon wins 50.40 MW overseas wind power project - 26-Jul-2017 09:50
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer